Who
Venrock Healthcare Capital Partners III, L.P.
10% owner
Company insider
Files Form 4 as: 10% owner, Lycia Therapeutics; 10% owner, KalVista Pharmaceuticals; 10% owner, Cogent Biosciences; 10% owner, Bellerophon Therapeutics.
In numbers
- Trades disclosed
- 33
- Buys
- 19
- Sells
- 5
- Bought
- $44.6M
- Sold
- $4.2M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 10 Sep 2018
- Last trade
- 27 Oct 2026
- Last filed
- 27 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Oct 2026filed 27 Oct 2026 | LYCA Lycia TherapeuticsBiotechnology | SEC FORM 4 Bought | $226K8,729 at $25.84 | filing |
| 27 Oct 2026filed 27 Oct 2026 | LYCA Lycia TherapeuticsBiotechnology | SEC FORM 4 Bought | $834K31,067 at $26.84 | filing |
| 26 Oct 2026filed 27 Oct 2026 | LYCA Lycia TherapeuticsBiotechnology | SEC FORM 4 Code C | —4,779,793 | filing |
| 26 Oct 2026filed 27 Oct 2026 | LYCA Lycia TherapeuticsBiotechnology | SEC FORM 4 Bought | $35.0M1,944,444 at $18.00 | filing |
| 26 Oct 2026filed 27 Oct 2026 | LYCA Lycia TherapeuticsBiotechnology | SEC FORM 4 Bought | $223K8,261 at $26.97 | filing |
| 26 Oct 2026filed 27 Oct 2026 | LYCA Lycia Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —17,142,578 at $0.00 | filing |
| 26 Oct 2026filed 27 Oct 2026 | LYCA Lycia Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —4,408,091 at $0.00 | filing |
| 23 Oct 2026filed 27 Oct 2026 | LYCA Lycia TherapeuticsBiotechnology | SEC FORM 4 Bought | $631K24,560 at $25.68 | filing |
| 23 Oct 2026filed 27 Oct 2026 | LYCA Lycia TherapeuticsBiotechnology | SEC FORM 4 Bought | $741K28,379 at $26.11 | filing |
| 26 Mar 2026filed 27 Mar 2026 | KalVista PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $380K21,386 at $17.76 | filing |
| 26 Mar 2026filed 27 Mar 2026 | KalVista PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $290K15,417 at $18.82 | filing |
| 26 Mar 2026filed 27 Mar 2026 | KalVista PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $61K3,183 at $19.12 | filing |
| 25 Mar 2026filed 27 Mar 2026 | KalVista PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $3.0M174,485 at $16.95 | filing |
| 25 Mar 2026filed 27 Mar 2026 | KalVista PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $2,805160 at $17.53 | filing |
| 11 Feb 2025filed 11 Feb 2025 | KalVista Pharmaceuticals | SEC FORM 4 Bought | $245K26,703 at $9.18 | filing |
| 10 Feb 2025filed 11 Feb 2025 | KalVista Pharmaceuticals | SEC FORM 4 Bought | $38K4,137 at $9.14 | filing |
| 7 Feb 2025filed 11 Feb 2025 | KalVista Pharmaceuticals | SEC FORM 4 Bought | $684K73,649 at $9.29 | filing |
| 30 Jan 2024filed 1 Feb 2024 | KalVista Pharmaceuticals | SEC FORM 4 Bought | $1.3M88,099 at $14.47 | filing |
| 29 Jan 2024filed 29 Jan 2024 | KalVista Pharmaceuticals | SEC FORM 4 Bought | $1.1M80,600 at $14.22 | filing |
| 26 Jan 2024filed 29 Jan 2024 | KalVista Pharmaceuticals | SEC FORM 4 Bought | $54K4,174 at $12.98 | filing |
News
Lycia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesLYCA · manilatimes.net · 26 Oct 2026HBM Portfolio Company Lycia Therapeutics Raises USD 317.5 Million in Nasdaq IPO and Delivers Strong Market DebutLYCA · finanzen.net · 26 Oct 2026
0 headlines in the last 90 days name Venrock Healthcare Capital Partners III, L.P.; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.